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To the Editor: In his excellent review, Meyrier1 outlined
the current ignorance about the pathogenesis of focal
segmental glomerulosclerosis (FSGS) and hoped for new
treatments aimed at counteracting the unknown factor(s)
responsible for FSGS rather than pursuing trials with agents
interfering with the immune system (or alternatively, acting
directly on the dysfunctional podocyte).
Although treatment of FSGS is still far from satisfactory,
the available data indicate that we are not ready to give up
these drugs, even though their use is driven by empiricism
rather than by a robust understanding of pathogenesis. A
treatment with oral glucocorticoids lasting 6 months or
more allows a remission (complete or partial) to be achieved
in about 60% of patients with FSGS and nephrotic
syndrome.2,3 The response to glucocorticoids is not confined
to patients with ‘tip’ lesions. In a series of patients studied,3
the response was not significantly different among the main
histological variants (classic scar 53%, collapsing lesion 64%,
‘tip’ lesion 78%). Patients who entered remission had a long-
term kidney survival significantly better than that observed
for untreated or non-responding patients.2,3 Calcineurin
inhibitors can also obtain a similar rate of response.4
Cytotoxic agents (for example, cyclophosphamide or chlor-
ambucil) have been almost abandoned, but a prolonged
administration, although potentially dangerous, may some-
times give a good rate of remission, when given as primary
therapy, and protect from relapses in steroid-responsive
patients.5
We concur with Meyrier on the pressing need for
characterizing the factors involved in FSGS and determining
their pathogenetic mechanisms. In the meantime, however,
we feel that so-called ‘immunosuppressive’ drugs still have a
role in the treatment of FSGS, whatever their mechanisms of
action.
1. Meyrier AY. Treatment of focal segmental glomerulosclerosis with
immunophilin modulation: when did we stop thinking about
pathogenesis? Kidney Int 2009; 76: 487–491.
2. Ponticelli C, Villa M, Banfi G et al. Can prolonged treatment improve the
prognosis in adults with focal segmental glomerulosclerosis? Am J Kidney
Dis 1999; 34: 618–625.
3. Chun MJ, Korbet SM, Schwartz MM et al. Focal segmental
glomerulosclerosis in nephrotic adults: presentation.prognosis, and
response to therapy of the histologic variants. J Am Soc Nephrol 2004; 15:
2169–2177.
4. Meyrier A. An update on the treatment options for segmental
glomerulosclerosis. Expert Opin Pharmacother 2009; 10:
615–628.
5. Banfi G, Moriggi M, Sabadini E et al. The impact of prolonged
immunosuppression on the outcome of idiopathic focal
segmental glomerulosclerosis with nephrotic syndrome in adults.
Clin Nephrol 1991; 36: 53–59.
Claudio E. Ponticelli1 and Richard J. Glassock2
1Divisione di Nefrologia e Dialisi – Istituto Scientifico Humanitas, Milan,
Italy and 2David Geffen School of Medicine at UCLA, Los Angeles,
California, USA
Correspondence: Claudio E. Ponticelli, Divisione di Nefrologia e Dialisi,
Istituto Scientifico Humanitas, via Manzoni 56, 20089 Rozzano,
Milan 20122, Italy. E-mail: claudio.ponticelli@fastwebnet.it
Response to ‘Treatment of focal
segmental glomerulosclerosis’
Kidney International (2010) 77, 259; doi:10.1038/ki.2009.452
The comments of Ponticelli and Glassock1 on my minireview2
are pertinent. As long as the factors that induce the
podocytopathy of focal segmental glomerulosclerosis (FSGS)
are not identified and counteracted, its treatment will be
based on immunosuppressants. I gave my reasons to believe
that FSGS is not a T-cell-driven autoimmune disease, and that
steroids and calcineurin inhibitors reduce proteinuria through
their pharmacological rather than immunosuppressive prop-
erties. This should not be considered as a recommendation to
change our current therapeutic options. I am less optimistic
about the results of steroids in cellular forms of FSGS, such as
collapsing glomerulopathy (CG), the definition of which has
been the subject of dissension among pathologists, dissension
that may explain differing figures in terms of remission.
Albaqumi et al.,3 in their review of 125 cases of CG, found a
meager figure (28%) for remissions. Likewise, I share the
opinion of Braun et al.,4 based on a Cochrane database
analysis, that alkylating agents are of no avail in steroid-
resistant FSGS. Notwithstanding these disagreements, I fully
agree on the fact that treatment of FSGS is mandatory.
Considering that an association of steroids and a calcineurin
inhibitor is credited with the best remission rates, and that
both classes of drugs are immunosuppressants but also
antiproteinuric agents, is reassuring. These drugs should be
used until other options based on new laboratory findings
lead to the elucidation of the etiology of one of the most
elusive causes of idiopathic nephrotic syndrome.
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